Pfizer Q2 2026 Earnings Top Estimates, Raises Outlook
Pfizer Q2 2026 earnings topped adjusted estimates and raised revenue guidance, supporting diversification driven by oncology and non-COVID strength.
KEY TAKEAWAYS
- Pfizer's Q2 adjusted EPS was $0.77, above analyst expectations of $0.68.
- Full-year revenue midpoint rose by $500 million.
- Non-COVID and oncology product growth underpinned the guidance lift.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Pfizer Inc. (NYSE: PFE) reported second-quarter 2026 earnings on Aug. 4, 2026, that exceeded Wall Street adjusted estimates. The company raised the midpoint of its full-year revenue guidance, reflecting strength in non-COVID and oncology sales despite posting a quarterly net loss.
Quarterly Results and Guidance Update
Pfizer’s adjusted earnings per share (EPS) for the quarter ended June 2026 was $0.77, surpassing analyst expectations of $0.68, according to the company’s press release. Revenue increased year-over-year, but the company recorded a net loss for the quarter, highlighting a divergence between its GAAP results and adjusted performance.
The company raised its 2026 revenue guidance by $500 million at the midpoint, revising the full-year range to $60.5 billion–$62.5 billion from $59.5 billion–$62.5 billion. Pfizer reaffirmed its adjusted diluted EPS guidance, which includes an approximate $0.10 per-share impact from the Innovent Biologics transaction.
Business Mix and Segment Performance
Growth in launched and acquired non-COVID products, particularly in oncology, helped offset declines in Pfizer’s COVID-19 portfolio. This shift in the business mix underpinned the company’s decision to raise revenue guidance, signaling progress in diversifying its revenue streams beyond COVID-related products.
